{"id":87615,"date":"2022-12-12T11:56:00","date_gmt":"2022-12-12T04:56:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022121211560087615"},"modified":"2022-12-12T22:15:23","modified_gmt":"2022-12-12T14:15:23","slug":"capivasertib%e8%81%94%e5%90%88%e8%8a%99%e4%bb%95%e5%be%97%e4%b8%8e%e8%8a%99%e4%bb%95%e5%be%97%e7%9b%b8%e6%af%94%e9%99%8d%e4%bd%8e%e6%99%9a%e6%9c%9fhr%e9%98%b3%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c40","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022121211560087615","title":{"rendered":"Capivasertib\u8054\u5408\u8299\u4ed5\u5f97\u4e0e\u8299\u4ed5\u5f97\u76f8\u6bd4\u964d\u4f4e\u665a\u671fHR\u9633\u6027\u4e73\u817a\u764c40%\u7684\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669"},"content":{"rendered":"

\u5728<\/i>SABCS 2022<\/i>\u4e0a\u516c\u5e03<\/i>\u7684<\/i>CAPItello-291III<\/i>\u671f\u8bd5\u9a8c\u7ed3\u679c\u663e\u793a<\/i>capivasertib<\/i>\u5177\u6709\u4f5c\u4e3a<\/i>first-in-class AKT<\/i>\u6fc0\u9176\u6291\u5236\u5242\u7684\u6f5c\u529b<\/i><\/p>\n

\u4e0a\u6d77<\/span>2022\u5e7412\u670812\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — CAPItello-291 III\u671f\u8bd5\u9a8c\u7684\u8be6\u7ec6\u7ed3\u679c\u663e\u793a\uff0c\u5bf9\u6fc0\u7d20\u53d7\u4f53\uff08HR\uff09\u9633\u6027\u3001\u4eba\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f532\uff08HER2\uff09\u4f4e\u8868\u8fbe\u6216\u9634\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\uff0c\u5728\u5185\u5206\u6ccc\u6cbb\u7597\u4e2d\u6216\u6cbb\u7597\u540e\uff08\u4f7f\u7528\u8fc7\u6216\u6ca1\u6709\u4f7f\u7528\u8fc7CDK4\/6\u6291\u5236\u5242\uff09\u590d\u53d1\u6216\u8fdb\u5c55\u540e\uff0c\u91c7\u7528\u963f\u65af\u5229\u5eb7\u7684capivasertib\u8054\u5408\u8299\u4ed5\u5f97\uff08\u901a\u7528\u540d\uff1a\u6c1f\u7ef4\u53f8\u7fa4\uff09\uff0c\u4e0e\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u76f8\u6bd4\uff0c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u548c\u4e34\u5e8a\u610f\u4e49\u7684\u6539\u5584[1]<\/sup>\u3002\u7ed3\u679c\u57282022\u5e74\u5723\u5b89\u4e1c\u5c3c\u5965\u4e73\u817a\u764c\u7814\u8ba8\u4f1a\uff08SABCS\uff09\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\u3002<\/p>\n

\u7ed3\u679c\u663e\u793a\uff0c\u5728\u603b\u4f53\u8bd5\u9a8c\u4eba\u7fa4\u4e2d\uff0ccapivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u4e0e\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u76f8\u6bd4\uff0c\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u7684\u98ce\u9669\u964d\u4f4e\u4e8640%\uff08\u57fa\u4e8e\u98ce\u9669\u6bd4[HR] 0.60\uff0c95%\u7f6e\u4fe1\u533a\u95f4[CI] 0.51-0.71\uff1bP=<0.001\uff1b\u4e2d\u4f4dPFS\u4e3a7.2\u6708\uff1a3.6\u6708\uff09[1]<\/sup>\u3002 \u5728AKT\u901a\u8def\u751f\u7269\u6807\u8bb0\u7269\u6539\u53d8\u7684\u4eba\u7fa4\u4e2d\uff0ccapivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u4e0e\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u76f8\u6bd4\uff0c\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u7684\u98ce\u9669\u964d\u4f4e\u4e8650%\uff08HR 0.50\uff0c95%CI 0.38-0.65\uff1bp=<0.001\uff1b\u4e2d\u4f4d\u6570\u4e3a7.3\u4e2a\u6708\uff1a3.1\u4e2a\u6708\uff09[1]<\/sup>\u3002 AKT\u901a\u8def\uff08PI3K\/AKT\/PTEN\uff09\u7684\u6539\u53d8\u5728\u4e73\u817a\u764c\u4e2d\u7ecf\u5e38\u53d1\u751f\uff0c\u5f71\u54cd\u591a\u8fbe50%\u7684HR\u9633\u6027\u665a\u671f\u4e73\u764c\u60a3\u8005[2-4]<\/sup>\u3002 <\/p>\n

\u4f26\u6566\u764c\u75c7\u7814\u7a76\u6240\u548c\u82f1\u56fd\u7687\u5bb6\u9a6c\u65af\u767bNHS\u57fa\u91d1\u4f1a\u7684\u5206\u5b50\u80bf\u7624\u5b66\u6559\u6388\uff0cCAPItello-291\u7684\u4e3b\u8981\u9996\u5e2d\u7814\u7a76\u5458Nicholas Turner\u535a\u58eb\u8868\u793a\uff1a\u201c\u8fd9\u4e9b\u6570\u636e\u663e\u793acapivasertib\u662f\u665a\u671fHR\u9633\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u65b0\u6cbb\u7597\u9009\u62e9\uff0c\u5177\u6709\u6539\u53d8\u4e34\u5e8a\u5b9e\u8df5\u7684\u6f5c\u529b\u3002\u91cd\u8981\u7684\u662f\uff0c\u8fd9\u79cd\u6f5c\u5728\u7684first-in-class\u7597\u6cd5\u663e\u793a\uff0c\u5728\u90a3\u4e9b\u5bf9\u5185\u5206\u6ccc\u7597\u6cd5\u548cCDK4\/6\u6291\u5236\u5242\u8010\u836f\u6cbb\u7597\u540e\u4ecd\u6709\u8fdb\u5c55\u7684\u60a3\u8005\u4e2d\uff0c\u5b83\u80fd\u5ef6\u7f13\u75be\u75c5\u8fdb\u5c55\u3002\u201d<\/p>\n

\u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\uff0c\u80bf\u7624\u6cbb\u7597\u9886\u57df\u7814\u53d1\u8d1f\u8d23\u4ebaSusan Galbraith\u8868\u793a\uff1a\u201cCapivasertib\u662f\u7b2c\u4e00\u4e2a\u5728III\u671f\u8bd5\u9a8c\u4e2d\u88ab\u8bc1\u660e\u5bf9\u665a\u671fHR\u9633\u6027\u3001HER2\u4f4e\u8868\u8fbe\u6216\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\u6709\u6548\u7684\u540c\u7c7b\u7597\u6cd5\uff0c\u7ed9\u8fd9\u4e2a\u4e00\u76f4\u5b58\u5728\u6cbb\u7597\u5dee\u8ddd\u7684\u9886\u57df\u5e26\u6765\u91cd\u8981\u8fdb\u5c55\u3002\u6211\u4eec\u76f8\u4fe1\uff0c\u5728\u6240\u6709\u60a3\u8005\u548c\u751f\u7269\u6807\u5fd7\u7269\u9633\u6027\u4eba\u7fa4\u4e2d\u90fd\u663e\u793a\u51fa\u7597\u6548\u7684\u8fd9\u4e9b\u7ed3\u679c\u53ef\u4ee5\u91cd\u5851HR\u9633\u6027\u4e73\u817a\u764c\u7684\u6cbb\u7597\uff0ccapivasertib\u80fd\u591f\u6210\u4e3a\u60a3\u8005\u7684\u4e00\u4e2a\u91cd\u8981\u7684\u65b0\u9009\u62e9\u3002\u201d<\/p>\n

\u8bd5\u9a8c\u7ed3\u679c\u6458\u8981\uff1a<\/b>CAPItello-291[1]<\/sup><\/b><\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n\n

Capivasertib<\/span><\/i><\/b>\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4<\/span><\/i><\/b> n=355<\/span><\/b><\/span><\/p>\n<\/td>\n

\n

\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4<\/span><\/i><\/b><\/span><\/p>\n

n=353<\/span><\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u603b\u4f53\u4eba\u7fa4\u4e2d\u7684\u4e2d\u4f4d<\/span>PFS<\/span>\uff08\u6708\uff09<\/span><\/p>\n<\/td>\n

\n

7.2<\/span><\/p>\n<\/td>\n

\n

3.6<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

HR (95% CI)<\/span><\/p>\n<\/td>\n

\n

0.60 (0.51-0.71)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

p-value<\/span><\/p>\n<\/td>\n

\n

p=<0.001<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u751f\u7269\u6807\u5fd7\u7269\u6539\u53d8\u4eba\u7fa4\u7684\u4e2d\u4f4d<\/span>PFS(<\/span>\u6708<\/span>)<\/span><\/p>\n<\/td>\n

\n

7.3<\/span><\/p>\n<\/td>\n

\n

3.1<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

HR (95% CI)<\/span><\/p>\n<\/td>\n

\n

0.50 (0.38-0.65)<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

p-value<\/span><\/p>\n<\/td>\n

\n

p=<0.001<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u603b\u4f53\u4eba\u7fa4\u4e2d\u7684<\/span>ORR<\/span><\/p>\n<\/td>\n

\n

22.9 %<\/span><\/p>\n<\/td>\n

\n

12.2 %<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u751f\u7269\u6807\u5fd7\u7269\u6539\u53d8\u4eba\u7fa4\u7684<\/span>ORR<\/span><\/p>\n<\/td>\n

\n

28.8 %<\/span><\/p>\n<\/td>\n

\n

9.7 %<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

HR\uff0c\u98ce\u9669\u6bd4\uff1bCI\uff0c\u7f6e\u4fe1\u533a\u95f4\uff1bPFS\uff0c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff1bORR\uff0c\u5ba2\u89c2\u53cd\u5e94\u7387\u3002<\/p>\n

\u5728\u6574\u4f53\u8bd5\u9a8c\u4eba\u7fa4\u4e2dcapivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u7ec4\u7684\u786e\u8ba4\u5ba2\u89c2\u53cd\u5e94\u7387\uff08ORR\uff09\u4e3a22.9%\uff0c\u800c\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u7ec4\u4e3a12.2%\uff0c\u5728\u751f\u7269\u6807\u5fd7\u7269\u6539\u53d8\u7684\u4eba\u7fa4\u4e2d\uff0cORR\u5206\u522b\u4e3a28.8%\u548c9.7%[1]<\/sup>\u3002\u5c3d\u7ba1\u5728\u5206\u6790\u65f6\u603b\u751f\u5b58\uff08OS\uff09\u6570\u636e\u8fd8\u4e0d\u6210\u719f\uff0c\u4f46\u65e9\u671f\u6570\u636e\u4ee4\u4eba\u9f13\u821e[1]<\/sup>\u3002\u8be5\u8bd5\u9a8c\u5c06\u7ee7\u7eed\u8bc4\u4f30OS\uff0c\u4f5c\u4e3a\u4e00\u4e2a\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u3002<\/p>\n

capivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u6cbb\u7597\u7684\u5b89\u5168\u6027\u4e0e\u4e4b\u524d\u8bc4\u4f30\u8fd9\u79cd\u8054\u5408\u7528\u836f\u7684\u8bd5\u9a8c\u4e2d\u89c2\u5bdf\u5230\u7684\u76f8\u4f3c[1]<\/sup>\u3002\u5728\u6574\u4f53\u8bd5\u9a8c\u4eba\u7fa4\u4e2d\uff0c20%\u53ca\u4ee5\u4e0a\u60a3\u8005\u5728\u4f7f\u7528capivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u65f6\u6700\u5e38\u89c1\u7684\u4efb\u4f55\u7ea7\u522b\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08AEs\uff09\u662f\u8179\u6cfb\uff0872.4%\uff09\u3001\u6076\u5fc3\uff0834. 6%\uff09\u3001\u76ae\u75b9\uff08\u5305\u62ec\u76ae\u75b9\u3001\u6591\u75b9\u3001\u6591\u4e18\u75b9\u548c\u7619\u75d2\u6027\u76ae\u75b9\uff1b38%\uff09\u3001\u75b2\u52b3\uff0820.8%\uff09\u548c\u5455\u5410\uff0820.6%\uff09[1]<\/sup>\u3002 5%\u53ca\u4ee5\u4e0a\u7684\u60a3\u8005\u6700\u5e38\u53d1\u751f\u76843\u7ea7\u6216\u4ee5\u4e0a\u7684AE\u662f\u8179\u6cfb\uff089.3%\uff09\u548c\u76ae\u75b9\uff0812.1%\uff09[1]<\/sup>\u3002 <\/p>\n

\u5173\u4e8e<\/b>HR<\/b>\u9633\u6027\u4e73\u817a\u764c<\/b><\/p>\n

\u4e73\u817a\u764c\u662f\u6700\u5e38\u89c1\u7684\u764c\u75c7\uff0c\u4e5f\u662f\u5168\u4e16\u754c\u764c\u75c7\u76f8\u5173\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\u4e4b\u4e00[5]<\/sup>\u30022020\u5e74\u6709\u8d85\u8fc7200\u4e07\u4eba\u88ab\u8bca\u65ad\u4e3a\u4e73\u817a\u764c\uff0c\u5168\u7403\u6709\u8fd168.5\u4e07\u4eba\u56e0\u6b64\u6b7b\u4ea1[5]<\/sup>\u3002<\/p>\n

HR\u9633\u6027\u4e73\u817a\u764c\uff08\u8868\u8fbe\u96cc\u6fc0\u7d20\u6216\u5b55\u6fc0\u7d20\u53d7\u4f53\uff0c\u6216\u4e24\u8005\u517c\u6709\uff09\uff0c\u662f\u6700\u5e38\u89c1\u7684\u4e73\u817a\u764c\u4e9a\u578b\uff0c\u5927\u7ea670%\u7684\u4e73\u817a\u764c\u88ab\u8ba4\u4e3a\u662fHR\u9633\u6027\uff0cHER2\u4f4e\u8868\u8fbe\u6216\u9634\u6027[6]<\/sup>\u3002<\/p>\n

HR\u9633\u6027\u4e73\u817a\u764c\u7ec6\u80de\u7684\u751f\u957f\u901a\u5e38\u7531\u96cc\u6fc0\u7d20\u53d7\u4f53\uff08ER\uff09\u9a71\u52a8[7]<\/sup>\uff0c\u9488\u5bf9ER\u9a71\u52a8\u75be\u75c5\u7684\u5185\u5206\u6ccc\u7597\u6cd5\u88ab\u5e7f\u6cdb\u7528\u4f5c\u665a\u671f\u4e73\u817a\u764c\u7684\u4e00\u7ebf\u6cbb\u7597\uff0c\u901a\u5e38\u4e0e\u5468\u671f\u86cb\u767d\u4f9d\u8d56\u6027\u6fc0\u9176\uff08CDK\uff094\/6\u6291\u5236\u5242\u8054\u5408[8,9]<\/sup> \u3002\u7136\u800c\uff0c\u8bb8\u591a\u665a\u671f\u75be\u75c5\u60a3\u8005\u5bf9CDK4\/6\u6291\u5236\u5242\u548c\u76ee\u524d\u5185\u5206\u6ccc\u7597\u6cd5\u4ea7\u751f\u8010\u836f\u6027[9]<\/sup>\u3002 \u4e00\u65e6\u53d1\u751f\u8fd9\u79cd\u60c5\u51b5\uff0c\u6cbb\u7597\u9009\u62e9\u5c31\u5f88\u6709\u9650[9]<\/sup> \uff0c\u5316\u7597\u662f\u76ee\u524d\u6807\u51c6\u7597\u6cd5[10]<\/sup>\uff0c\u4f46\u751f\u5b58\u7387\u5f88\u4f4e\uff0c\u9884\u4f30\u4ec530%\u7684\u60a3\u8005\u5728\u8bca\u65ad\u540e\u80fd\u5b58\u6d3b\u8d85\u8fc7\u4e94\u5e74[6]<\/sup>\u3002<\/p>\n

\u4f18\u5316\u5185\u5206\u6ccc\u6cbb\u7597\uff0c\u514b\u670dER\u9a71\u52a8\u75be\u75c5\u60a3\u8005\u5728\u6240\u6709\u6cbb\u7597\u9636\u6bb5\u7684\u8010\u836f\u6027\uff0c\u4ee5\u53ca\u4e3a\u4e0d\u518d\u6709ER\u9a71\u52a8\u75be\u75c5\u7684\u60a3\u8005\u786e\u5b9a\u65b0\u7684\u6cbb\u7597\u65b9\u6cd5\uff0c\u662f\u4e73\u817a\u764c\u7814\u7a76\u7684\u79ef\u6781\u91cd\u70b9\u9886\u57df\u3002<\/p>\n

\u5173\u4e8e<\/b>CAPItello-291<\/b><\/p>\n

CAPItello-291\u662f\u4e00\u9879\u5168\u7403\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u53cc\u76f2\u3001\u968f\u673a\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u662fAKT\u6291\u5236\u5242capivasertib\u4e34\u5e8a\u9879\u76ee\u7684\u4e00\u90e8\u5206\uff0c\u65e8\u5728\u8bc4\u4f30capivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u5bf9\u6bd4\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u6cbb\u7597\u5c40\u90e8\u665a\u671f\uff08\u4e0d\u53ef\u624b\u672f\uff09\u6216\u8f6c\u79fb\u6027HR\u9633\u6027\uff0cHER2\u4f4e\u8868\u8fbe\u6216\u9634\u6027\u4e73\u817a\u764c\u7684\u7597\u6548\u3002<\/p>\n

\u8fd9\u9879\u5168\u7403\u7814\u7a76\u62db\u52df\u4e86708\u4f8b\u7ecf\u7ec4\u7ec7\u5b66\u8bc1\u5b9e\u4e3aHR\u9633\u6027\u3001HER2\u4f4e\u8868\u8fbe\u6216\u9634\u6027\u4e73\u817a\u764c\u7684\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u5728\u63a5\u53d7\u82b3\u9999\u5316\u9176\u6291\u5236\u5242\uff08AI\uff09\u6cbb\u7597\u671f\u95f4\u6216\u6cbb\u7597\u540e\u75be\u75c5\u590d\u53d1\u6216\u8fdb\u5c55\uff0c\u53ef\u4f7f\u7528\u8fc7\u6216\u6ca1\u6709\u4f7f\u7528\u8fc7CDK4\/6\u6291\u5236\u5242\uff0c\u60a3\u8005\u9488\u5bf9\u665a\u671f\u75be\u75c5\u81f3\u591a\u8fdb\u884c\u4e00\u7ebf\u5316\u7597\u3002\u8be5\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u4e3a\u603b\u4f53\u4eba\u7fa4\u548c\u643a\u5e26PIK3CA\/AKT1\/PTEN\u57fa\u56e0\u7a81\u53d8\u60a3\u8005\u4e9a\u7ec4\u7684\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u3002\u5728\u7814\u7a76\u4e2d\uff0c\u7ea640%\u7684\u60a3\u8005\u6709PI3K\/AKT\/PTEN\u7a81\u53d8\u3002<\/p>\n

\u5173\u4e8e<\/b>Capivasertib<\/b><\/p>\n

Capivasertib\u662f\u4e00\u79cd\u5728\u7814\u7a76\u4e2d\u7684\u53e3\u670d\u6cbb\u7597\u836f\u7269\uff0c\u76ee\u524d\u6b63\u5904\u4e8e\u6cbb\u7597\u591a\u79cd\u4e9a\u578b\u4e73\u817a\u764c\u3001\u524d\u5217\u817a\u764c\u7684III\u671f\u8bd5\u9a8c\u4e2d\uff0c\u540c\u65f6\u4e5f\u5728\u6cbb\u7597\u8840\u6db2\u80bf\u7624\u7684II\u671f\u8bd5\u9a8c\u4e2d\u3002Capivasertib\u662f\u4e00\u79cd\u6709\u6548\u7684\u3001\u9009\u62e9\u6027\u7684\u4e09\u78f7\u9178\u817a\u82f7\uff08ATP\uff09\u7ade\u4e89\u6027\u6291\u5236\u5242\uff0c\u53ef\u6291\u5236\u5168\u90e8\u4e09\u79cd\u7684AKT\u4e9a\u578b\uff08AKT1\/2\/3\uff09\u3002\u76ee\u524d\uff0ccapivasertib\u4e0e\u73b0\u6709\u7684\u6cbb\u7597\u65b9\u6848\u8054\u7528\uff0c\u7528\u4e8ePI3K\/AKT\/PTEN\u901a\u8def\u53d1\u751f\u6539\u53d8\u7684\u80bf\u7624\uff0c\u4ee5\u53ca\u4f9d\u8d56\u8be5\u4fe1\u53f7\u901a\u8def\u7684\u80bf\u7624\u3002\u6839\u636e\u65e9\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u8010\u53d7\u6027\u548c\u9776\u6807\u6291\u5236\u7a0b\u5ea6\u7ed3\u679c\uff0cCapivasertib 400mg\u91c7\u53d6\u95f4\u6b47\u6027\u7ed9\u836f\uff0c\u8fde\u7eed\u7528\u836f4\u5929\u540e\u6682\u505c3\u5929\u3002<\/p>\n

Capivasertib\u4e34\u5e8a\u7814\u7a76\u9879\u76ee\u65e8\u5728\u89c2\u5bdfcapivasertib\u4e0e\u65e2\u5b9a\u6cbb\u7597\u65b9\u6848\u8054\u5408\u5e94\u7528\u65f6\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002<\/p>\n

Capivasertib\u662f\u963f\u65af\u5229\u5eb7\u4e0eAstex Therapeutics \u5408\u4f5c\uff08\u4ee5\u53ca\u4e0e\u4f26\u6566\u764c\u75c7\u7814\u7a76\u6240\u548c\u764c\u75c7\u7814\u7a76\u6280\u672f\u6709\u9650\u516c\u53f8\u7684\u5408\u4f5c\uff09\u4e4b\u540e\u5f00\u53d1\u7684\u3002<\/p>\n

\u5173\u4e8e\u963f\u65af\u5229\u5eb7\u5728\u4e73\u817a\u764c\u9886\u57df\u7684\u7814\u7a76<\/b><\/p>\n

\u968f\u7740\u5bf9\u4e73\u817a\u764c\u751f\u7269\u5b66\u7684\u65e5\u76ca\u4e86\u89e3\uff0c\u963f\u65af\u5229\u5eb7\u5f00\u59cb\u6311\u6218\u548c\u91cd\u65b0\u5b9a\u4e49\u4e73\u817a\u764c\u7684\u5206\u7c7b\u53ca\u4e34\u5e8a\u6cbb\u7597\u6a21\u5f0f\uff0c\u4ee5\u63d0\u4f9b\u7ed9\u60a3\u8005\u6240\u9700\u7684\u66f4\u4e3a\u7cbe\u51c6\u800c\u6709\u6548\u7684\u6cbb\u7597\u65b9\u6848\u3002\u963f\u65af\u5229\u5eb7\u96c4\u5fc3\u52c3\u52c3\uff0c\u5e0c\u671b\u6709\u671d\u4e00\u65e5\u53ef\u4ee5\u6d88\u9664\u4e73\u817a\u764c\u8fd9\u4e00\u81f4\u6b7b\u75c5\u56e0\u3002<\/p>\n

\u963f\u65af\u5229\u5eb7\u7814\u53d1\u4e86\u4e00\u7cfb\u5217\u5df2\u83b7\u6279\u6216\u6709\u671b\u83b7\u6279\u7684\u836f\u7269\uff0c\u901a\u8fc7\u591a\u79cd\u673a\u5236\u5e94\u5bf9\u4e73\u817a\u764c\u80bf\u7624\u5fae\u73af\u5883\u7684\u751f\u7269\u591a\u6837\u6027\u3002<\/p>\n

\u51ed\u501f\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\uff08trastuzumab deruxtecan\uff09\uff0c\u4e00\u79cd\u9776\u5411HER2\u7684\u6297\u4f53\u5076\u8054\u836f\u7269\uff0c\u963f\u65af\u5229\u5eb7\u548c\u7b2c\u4e00\u4e09\u5171\u7684\u76ee\u6807\u662f\u6539\u5584\u5148\u524d\u6cbb\u7597\u7684HER2\u9633\u6027\u548cHER2\u4f4e\u8868\u8fbe\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u7684\u7ed3\u679c\uff0c\u5e76\u6b63\u5728\u63a2\u7d22\u5176\u5728\u66f4\u65e9\u7ebf\u7684\u6cbb\u7597\u548c\u65b0\u578b\u4e73\u817a\u764c\u4e2d\u7684\u6f5c\u529b\u3002<\/p>\n

\u5728HR\u9633\u6027\u4e73\u817a\u764c\u4e2d\uff0c\u963f\u65af\u5229\u5eb7\u7ee7\u7eed\u6301\u7eed\u57fa\u77f3\u836f\u7269\u6c1f\u7ef4\u53f8\u7fa4\u548c\u6208\u820d\u745e\u6797\u6539\u5584\u9884\u540e\uff0c\u5e76\u65e8\u5728\u901a\u8fc7ngSERD camizestrant\u548c\u6f5c\u5728\u65b0\u836fAKT\u6fc0\u9176\u6291\u5236\u5242capivasertib\u91cd\u5851HR\u9633\u6027\u4e73\u817a\u764c\u6cbb\u7597\u3002\u540c\u65f6\uff0c\u963f\u65af\u5229\u5eb7\u4e0e\u7b2c\u4e00\u4e09\u5171\u5408\u4f5c\uff0c\u63a2\u7d22 TROP2\u9776\u5411ADC datopotamab deruxtecan\u7684\u6f5c\u5728\u6548\u679c\u3002<\/p>\n

PARP\u6291\u5236\u5242\u5965\u62c9\u5e15\u5229\u662f\u4e00\u79cd\u9776\u5411\u6cbb\u7597\u9009\u62e9\uff0c\u5df2\u5728\u9057\u4f20\u6027BRCA\u7a81\u53d8\u7684 HER2\u9634\u6027\u65e9\u671f\u548c\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u4e2d\u8fdb\u884c\u4e86\u7814\u7a76\u3002\u963f\u65af\u5229\u5eb7\u548c\u9ed8\u6c99\u4e1c\u6301\u7eed\u63a2\u7d22\u5965\u62c9\u5e15\u5229\u5728BRCA\u9057\u4f20\u7a81\u53d8\u7684\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\u4e2d\u7684\u6548\u679c\uff0c\u540c\u65f6\u6b63\u5bfb\u6c42\u65b0\u7684\u5951\u673a\u4f7f\u8fd9\u7c7b\u60a3\u8005\u5728\u75be\u75c5\u66f4\u65e9\u671f\u63a5\u53d7\u6cbb\u7597\u3002<\/p>\n

\u4e3a\u4e86\u6ee1\u8db3\u4e09\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\u5bf9\u66f4\u591a\u6cbb\u7597\u9009\u62e9\u7684\u8feb\u5207\u9700\u6c42\uff0c\u963f\u65af\u5229\u5eb7\u6b63\u5728\u8bc4\u4f30datopotamab deruxtecan\u5355\u72ec\u4f7f\u7528\u548c\u4e0e\u514d\u75ab\u7597\u6cd5durvalumab\u8054\u5408\u4f7f\u7528\u7684\u6f5c\u529b\uff0c\u8bc4\u4f30capivasertib\u4e0e\u5316\u7597\u8054\u5408\u4f7f\u7528\uff0c\u4ee5\u53cadurvalumab\u4e0e\u5176\u4ed6\u80bf\u7624\u836f\u7269\uff0c\u5305\u62ec\u5965\u62c9\u5e15\u5229\u548c\u5fb7\u66f2\u59a5\u73e0\u5355\u6297\u8054\u5408\u4f7f\u7528\u7684\u6548\u679c\u3002<\/p>\n

\u5173\u4e8e\u963f\u65af\u5229\u5eb7\u5728\u80bf\u7624\u9886\u57df\u7684\u7814\u7a76<\/b><\/p>\n

\u963f\u65af\u5229\u5eb7\u6b63\u5f15\u9886\u7740\u80bf\u7624\u9886\u57df\u7684\u4e00\u573a\u9769\u547d\uff0c\u81f4\u529b\u63d0\u4f9b\u591a\u5143\u5316\u7684\u80bf\u7624\u6cbb\u7597\u65b9\u6848\uff0c\u4ee5\u79d1\u5b66\u63a2\u7d22\u80bf\u7624\u9886\u57df\u7684\u590d\u6742\u6027\uff0c\u53d1\u73b0\u3001\u7814\u53d1\u5e76\u5411\u60a3\u8005\u63d0\u4f9b\u6539\u53d8\u751f\u547d\u7684\u836f\u7269\u3002<\/p>\n

\u963f\u65af\u5229\u5eb7\u4e13\u6ce8\u4e8e\u6700\u5177\u6311\u6218\u6027\u7684\u80bf\u7624\u75be\u75c5\uff0c\u901a\u8fc7\u6301\u7eed\u4e0d\u65ad\u7684\u521b\u65b0\uff0c\u963f\u65af\u5229\u5eb7\u5df2\u7ecf\u5efa\u7acb\u4e86\u884c\u4e1a\u9886\u5148\u7684\u591a\u5143\u5316\u7684\u4ea7\u54c1\u7ec4\u5408\u548c\u7ba1\u7ebf\uff0c\u6301\u7eed\u63a8\u52a8\u533b\u7597\u5b9e\u8df5\u53d8\u9769\uff0c\u6539\u53d8\u60a3\u8005\u4f53\u9a8c\u3002<\/p>\n

\u963f\u65af\u5229\u5eb7\u4ee5\u671f\u91cd\u65b0\u5b9a\u4e49\u764c\u75c7\u6cbb\u7597\u5e76\u5728\u672a\u6765\u653b\u514b\u764c\u75c7\u3002<\/p>\n

\u5173\u4e8e\u963f\u65af\u5229\u5eb7<\/b><\/p>\n

\u963f\u65af\u5229\u5eb7\uff08LSE\/STO\/Nasdaq: AZN\uff09\u662f\u4e00\u5bb6\u79d1\u5b66\u81f3\u4e0a\u7684\u5168\u7403\u6027\u751f\u7269\u5236\u836f\u4f01\u4e1a\uff0c\u4e13\u6ce8\u4e8e\u7814\u53d1\u3001\u751f\u4ea7\u53ca\u8425\u9500\u5904\u65b9\u7c7b\u836f\u54c1\uff0c\u91cd\u70b9\u5173\u6ce8\u80bf\u7624\u3001\u7f55\u89c1\u75c5\u548c\u751f\u7269\u533b\u836f\uff0c\u5305\u62ec\u5fc3\u8840\u7ba1\u3001\u80be\u810f\u53ca\u4ee3\u8c22\u3001\u547c\u5438\u53ca\u514d\u75ab\u3002\u963f\u65af\u5229\u5eb7\u5168\u7403\u603b\u90e8\u4f4d\u4e8e\u82f1\u56fd\u5251\u6865\uff0c\u4e1a\u52a1\u904d\u5e03\u4e16\u754c100\u591a\u4e2a\u56fd\u5bb6\uff0c\u521b\u65b0\u836f\u7269\u60e0\u53ca\u5168\u7403\u6570\u767e\u4e07\u60a3\u8005\u3002\u66f4\u591a\u4fe1\u606f\uff0c\u8bf7\u8bbf\u95eewww.astrazeneca.com<\/a>\u3002<\/p>\n

\u58f0\u660e<\/b><\/p>\n

\u672c\u6587\u6d89\u53ca\u7814\u7a76\u4e2d\u7684\u836f\u54c1\u7528\u6cd5\u5c1a\u672a\u5728\u4e2d\u56fd\u83b7\u6279\u9002\u5e94\u75c7\uff0c\u963f\u65af\u5229\u5eb7\u4e0d\u63a8\u8350\u4efb\u4f55\u672a\u88ab\u6279\u51c6\u7684\u836f\u54c1\u4f7f\u7528\u3002<\/p>\n

\u53c2\u8003\u6587\u732e<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

1. Turner, et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial. Presented at: San Antonio Breast Cancer Symposium, 6-10 December 2022, San Antonio, Texas, USA.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

2. Howell S J, et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION). J Clin Oncol.<\/i> 2022; 23:851-64.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

3. Hortobagyi G N, et al. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol.<\/i> 2016; 34:419-26.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

4. Millis S Z, et al. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol.<\/i> 2016;2(12):1565-73.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

5. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin.<\/i> 2021; 10.3322\/caac.21660.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

6. National Cancer Institute. Surveillance, Epidemiology and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html<\/a>. Accessed December 2022.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

7. Scabia V, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nat Commun.<\/i> 2022; 10.1038\/s41467-022-30898-0.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

8. Lin M, et al. Comparative Overall Survival of CDK4\/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer.<\/i> 2020; 10.7150\/jca.48944.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

9. Lloyd M R, et al. Mechanisms of Resistance to CDK4\/6 Blockade in Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res.<\/i> 2022;28(5):821-30.<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

10. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Available at: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419<\/a>. Accessed December 2022. <\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

\u5728SABCS 2022\u4e0a\u516c\u5e03\u7684CAPItello-291III\u671f\u8bd5\u9a8c\u7ed3\u679c\u663e\u793acapivasertib\u5177\u6709\u4f5c\u4e3afirst-in-class AKT\u6fc0\u9176\u6291\u5236\u5242\u7684\u6f5c\u529b \u4e0a\u6d772022\u5e7412\u670812\u65e5 \/\u7f8e\u901a\u793e\/ — CAPItello-291 III\u671f\u8bd5\u9a8c\u7684\u8be6\u7ec6\u7ed3\u679c\u663e\u793a\uff0c\u5bf9\u6fc0\u7d20\u53d7\u4f53\uff08HR\uff09\u9633\u6027\u3001\u4eba\u8868\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f532\uff08HER2\uff09\u4f4e\u8868\u8fbe\u6216\u9634\u6027\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u4e73\u817a\u764c\u60a3\u8005\uff0c\u5728\u5185\u5206\u6ccc\u6cbb\u7597\u4e2d\u6216\u6cbb\u7597\u540e\uff08\u4f7f\u7528\u8fc7\u6216\u6ca1\u6709\u4f7f\u7528\u8fc7CDK4\/6\u6291\u5236\u5242\uff09\u590d\u53d1\u6216\u8fdb\u5c55\u540e\uff0c\u91c7\u7528\u963f\u65af\u5229\u5eb7\u7684capivasertib\u8054\u5408\u8299\u4ed5\u5f97\uff08\u901a\u7528\u540d\uff1a\u6c1f\u7ef4\u53f8\u7fa4\uff09\uff0c\u4e0e\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u76f8\u6bd4\uff0c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u5177\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u548c\u4e34\u5e8a\u610f\u4e49\u7684\u6539\u5584[1]\u3002\u7ed3\u679c\u57282022\u5e74\u5723\u5b89\u4e1c\u5c3c\u5965\u4e73\u817a\u764c\u7814\u8ba8\u4f1a\uff08SABCS\uff09\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\u3002 \u7ed3\u679c\u663e\u793a\uff0c\u5728\u603b\u4f53\u8bd5\u9a8c\u4eba\u7fa4\u4e2d\uff0ccapivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u4e0e\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u76f8\u6bd4\uff0c\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u7684\u98ce\u9669\u964d\u4f4e\u4e8640%\uff08\u57fa\u4e8e\u98ce\u9669\u6bd4[HR] 0.60\uff0c95%\u7f6e\u4fe1\u533a\u95f4[CI] 0.51-0.71\uff1bP=<0.001\uff1b\u4e2d\u4f4dPFS\u4e3a7.2\u6708\uff1a3.6\u6708\uff09[1]\u3002 \u5728AKT\u901a\u8def\u751f\u7269\u6807\u8bb0\u7269\u6539\u53d8\u7684\u4eba\u7fa4\u4e2d\uff0ccapivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u4e0e\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u76f8\u6bd4\uff0c\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u7684\u98ce\u9669\u964d\u4f4e\u4e8650%\uff08HR 0.50\uff0c95%CI 0.38-0.65\uff1bp=<0.001\uff1b\u4e2d\u4f4d\u6570\u4e3a7.3\u4e2a\u6708\uff1a3.1\u4e2a\u6708\uff09[1]\u3002 AKT\u901a\u8def\uff08PI3K\/AKT\/PTEN\uff09\u7684\u6539\u53d8\u5728\u4e73\u817a\u764c\u4e2d\u7ecf\u5e38\u53d1\u751f\uff0c\u5f71\u54cd\u591a\u8fbe50%\u7684HR\u9633\u6027\u665a\u671f\u4e73\u764c\u60a3\u8005[2-4]\u3002  \u4f26\u6566\u764c\u75c7\u7814\u7a76\u6240\u548c\u82f1\u56fd\u7687\u5bb6\u9a6c\u65af\u767bNHS\u57fa\u91d1\u4f1a\u7684\u5206\u5b50\u80bf\u7624\u5b66\u6559\u6388\uff0cCAPItello-291\u7684\u4e3b\u8981\u9996\u5e2d\u7814\u7a76\u5458Nicholas Turner\u535a\u58eb\u8868\u793a\uff1a\u201c\u8fd9\u4e9b\u6570\u636e\u663e\u793acapivasertib\u662f\u665a\u671fHR\u9633\u6027\u4e73\u817a\u764c\u60a3\u8005\u7684\u65b0\u6cbb\u7597\u9009\u62e9\uff0c\u5177\u6709\u6539\u53d8\u4e34\u5e8a\u5b9e\u8df5\u7684\u6f5c\u529b\u3002\u91cd\u8981\u7684\u662f\uff0c\u8fd9\u79cd\u6f5c\u5728\u7684first-in-class\u7597\u6cd5\u663e\u793a\uff0c\u5728\u90a3\u4e9b\u5bf9\u5185\u5206\u6ccc\u7597\u6cd5\u548cCDK4\/6\u6291\u5236\u5242\u8010\u836f\u6cbb\u7597\u540e\u4ecd\u6709\u8fdb\u5c55\u7684\u60a3\u8005\u4e2d\uff0c\u5b83\u80fd\u5ef6\u7f13\u75be\u75c5\u8fdb\u5c55\u3002\u201d \u963f\u65af\u5229\u5eb7\u5168\u7403\u6267\u884c\u526f\u603b\u88c1\uff0c\u80bf\u7624\u6cbb\u7597\u9886\u57df\u7814\u53d1\u8d1f\u8d23\u4ebaSusan Galbraith\u8868\u793a\uff1a\u201cCapivasertib\u662f\u7b2c\u4e00\u4e2a\u5728III\u671f\u8bd5\u9a8c\u4e2d\u88ab\u8bc1\u660e\u5bf9\u665a\u671fHR\u9633\u6027\u3001HER2\u4f4e\u8868\u8fbe\u6216\u9634\u6027\u4e73\u817a\u764c\u60a3\u8005\u6709\u6548\u7684\u540c\u7c7b\u7597\u6cd5\uff0c\u7ed9\u8fd9\u4e2a\u4e00\u76f4\u5b58\u5728\u6cbb\u7597\u5dee\u8ddd\u7684\u9886\u57df\u5e26\u6765\u91cd\u8981\u8fdb\u5c55\u3002\u6211\u4eec\u76f8\u4fe1\uff0c\u5728\u6240\u6709\u60a3\u8005\u548c\u751f\u7269\u6807\u5fd7\u7269\u9633\u6027\u4eba\u7fa4\u4e2d\u90fd\u663e\u793a\u51fa\u7597\u6548\u7684\u8fd9\u4e9b\u7ed3\u679c\u53ef\u4ee5\u91cd\u5851HR\u9633\u6027\u4e73\u817a\u764c\u7684\u6cbb\u7597\uff0ccapivasertib\u80fd\u591f\u6210\u4e3a\u60a3\u8005\u7684\u4e00\u4e2a\u91cd\u8981\u7684\u65b0\u9009\u62e9\u3002\u201d \u8bd5\u9a8c\u7ed3\u679c\u6458\u8981\uff1aCAPItello-291[1] Capivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4 n=355 \u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4 n=353 \u603b\u4f53\u4eba\u7fa4\u4e2d\u7684\u4e2d\u4f4dPFS\uff08\u6708\uff09 7.2 3.6 HR (95% CI) 0.60 (0.51-0.71) p-value p=<0.001 \u751f\u7269\u6807\u5fd7\u7269\u6539\u53d8\u4eba\u7fa4\u7684\u4e2d\u4f4dPFS(\u6708) 7.3 3.1 HR (95% CI) 0.50 (0.38-0.65) p-value p=<0.001 \u603b\u4f53\u4eba\u7fa4\u4e2d\u7684ORR 22.9 % 12.2 % \u751f\u7269\u6807\u5fd7\u7269\u6539\u53d8\u4eba\u7fa4\u7684ORR 28.8 % 9.7 % HR\uff0c\u98ce\u9669\u6bd4\uff1bCI\uff0c\u7f6e\u4fe1\u533a\u95f4\uff1bPFS\uff0c\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff1bORR\uff0c\u5ba2\u89c2\u53cd\u5e94\u7387\u3002 \u5728\u6574\u4f53\u8bd5\u9a8c\u4eba\u7fa4\u4e2dcapivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u7ec4\u7684\u786e\u8ba4\u5ba2\u89c2\u53cd\u5e94\u7387\uff08ORR\uff09\u4e3a22.9%\uff0c\u800c\u5b89\u6170\u5242\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u7ec4\u4e3a12.2%\uff0c\u5728\u751f\u7269\u6807\u5fd7\u7269\u6539\u53d8\u7684\u4eba\u7fa4\u4e2d\uff0cORR\u5206\u522b\u4e3a28.8%\u548c9.7%[1]\u3002\u5c3d\u7ba1\u5728\u5206\u6790\u65f6\u603b\u751f\u5b58\uff08OS\uff09\u6570\u636e\u8fd8\u4e0d\u6210\u719f\uff0c\u4f46\u65e9\u671f\u6570\u636e\u4ee4\u4eba\u9f13\u821e[1]\u3002\u8be5\u8bd5\u9a8c\u5c06\u7ee7\u7eed\u8bc4\u4f30OS\uff0c\u4f5c\u4e3a\u4e00\u4e2a\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u3002 capivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u6cbb\u7597\u7684\u5b89\u5168\u6027\u4e0e\u4e4b\u524d\u8bc4\u4f30\u8fd9\u79cd\u8054\u5408\u7528\u836f\u7684\u8bd5\u9a8c\u4e2d\u89c2\u5bdf\u5230\u7684\u76f8\u4f3c[1]\u3002\u5728\u6574\u4f53\u8bd5\u9a8c\u4eba\u7fa4\u4e2d\uff0c20%\u53ca\u4ee5\u4e0a\u60a3\u8005\u5728\u4f7f\u7528capivasertib\u8054\u5408\u6c1f\u7ef4\u53f8\u7fa4\u65f6\u6700\u5e38\u89c1\u7684\u4efb\u4f55\u7ea7\u522b\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08AEs\uff09\u662f\u8179\u6cfb\uff0872.4%\uff09\u3001\u6076\u5fc3\uff0834. 6%\uff09\u3001\u76ae\u75b9\uff08\u5305\u62ec\u76ae\u75b9\u3001\u6591\u75b9\u3001\u6591\u4e18\u75b9\u548c\u7619\u75d2\u6027\u76ae\u75b9\uff1b38%\uff09\u3001\u75b2\u52b3\uff0820.8%\uff09\u548c\u5455\u5410\uff0820.6%\uff09[1]\u3002 5%\u53ca\u4ee5\u4e0a\u7684\u60a3\u8005\u6700\u5e38\u53d1\u751f\u76843\u7ea7\u6216\u4ee5\u4e0a\u7684AE\u662f\u8179\u6cfb\uff089.3%\uff09\u548c\u76ae\u75b9\uff0812.1%\uff09[1]\u3002  \u5173\u4e8eHR\u9633\u6027\u4e73\u817a\u764c… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-87615","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/87615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=87615"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/87615\/revisions"}],"predecessor-version":[{"id":87616,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/87615\/revisions\/87616"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=87615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=87615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=87615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}